Prohibitin and the extracellular matrix are upregulated in murine alveolar epithelial cells with LPS‑induced acute injury

Zhang,Feng; Fan,Dejun; Mo,Xiao‑Neng

doi:10.3892/mmr.2018.8808

Prohibitin and the extracellular matrix are upregulated in murine alveolar epithelial cells with LPS‑induced acute injury

Authors:
- Feng Zhang
- Dejun Fan
- Xiao‑Neng Mo
View Affiliations

Affiliations: Department of Respiratory Medicine, The Sixth Affiliated Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510655, P.R. China, Department of Gastrointestinal Endoscopy, The Sixth Affiliated Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510655, P.R. China
Published online on: March 28, 2018 https://doi.org/10.3892/mmr.2018.8808
Pages: 7769-7773

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inflammation of epithelial and endothelial cells accelerates the progress of acute lung injury (ALI), and pulmonary fibrosis is the leading cause of mortality in patients with acute respiratory distress syndrome. Interleukin‑6 (IL‑6) is a pleiotropic cytokine implicated in the pathogenesis of a number of immune‑mediated disorders, and is involved in pulmonary fibrosis. Prohibitin (PHB) is a highly conserved protein implicated in various cellular functions, including proliferation, apoptosis, tumor suppression, transcription and mitochondrial protein folding. PHB was identified to be associated with a variety of pulmonary diseases, including pulmonary fibrosis. Based on the lipopolysaccharide (LPS)‑induced cell model of ALI, the present study examined the expression of PHB and the extracellular matrix (ECM) in the process of pulmonary inflammation. MLE‑12 cells were divided into 2 groups: The control group was administered sterile PBS; the treatment group was administered 500 ng/ml LPS for 12 h. The mRNA expression of IL‑6 in the treatment group was significantly upregulated compared with the control group (P<0.05). The protein expression of IL‑6 in the treatment group was markedly increased compared with the control group (P<0.05). ECM components, including collagen‑IV and fibronectin, in the treatment group were markedly increased when compared with the control group (P<0.05). The mRNA and protein expression levels of PHB1 and PHB2 were significantly upregulated following treatment with LPS (both P<0.05). The present study identified that PHB and ECM component levels increased in the LPS‑induced ALI cell model, and further investigations may be performed to verify the detailed mechanism.

View Figures

View References

1	Luh SP and Chiang CH: Acute lung injury/acute respiratory distress syndrome (ALI/ARDS): The mechanism, present strategies and future perspectives of therapies. J Zhejiang Univ Sci B. 8:60–69. 2007. View Article : Google Scholar : PubMed/NCBI
2	Matthay MA, Ware LB and Zimmerman GA: The acute respiratory distress syndrome. J Clin Invest. 122:2731–2740. 2012. View Article : Google Scholar : PubMed/NCBI
3	Tomashefski JF Jr: Pulmonary pathology of acute respiratory distress syndrome. Clin Chest Med. 21:435–466. 2000. View Article : Google Scholar : PubMed/NCBI
4	Ware LB and Matthay MA: The acute respiratory distress syndrome. N Engl J Med. 342:1334–1349. 2000. View Article : Google Scholar : PubMed/NCBI
5	Orme JJ, Romney JS, Hopkins RO, Pope D, Chan KJ, Thomsen G, Crapo RO and Weaver LK: Pulmonary function and health-related quality of life in survivors of acute respiratory distress syndrome. Am J Respir Crit Care Med. 167:690–694. 2003. View Article : Google Scholar : PubMed/NCBI
6	Chida M, Ono S, Hoshikawa Y and Kondo T: Subclinical idiopathic pulmonary fibrosis is also a risk factor of postoperative acute respiratory distress syndrome following thoracic surgery. Eur J Cardiothorac Surg. 34:878–881. 2008. View Article : Google Scholar : PubMed/NCBI
7	Fukuda Y, Ishizaki M, Masuda Y, Kimura G, Kawanami O and Masugi Y: The role of intraalveolar fibrosis in the process of pulmonary structural remodeling in patients with diffuse alveolar damage. Am J Pathol. 126:171–182. 1987.PubMed/NCBI
8	Lin P: Targeting interleukin-6 for noninfectious uveitis. Clin Ophthalmol. 9:1697–1702. 2015. View Article : Google Scholar : PubMed/NCBI
9	Rose-John S: The soluble interleukin-6 receptor and related proteins. Best Pract Res Clin Endocrinol Metab. 29:787–797. 2015. View Article : Google Scholar : PubMed/NCBI
10	De Lauretis A, Sestini P, Pantelidis P, Hoyles R, Hansell DM, Goh NS, Zappala CJ, Visca D, Maher TM, Denton CP, et al: Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol. 40:435–446. 2013. View Article : Google Scholar : PubMed/NCBI
11	O'Donoghue RJ, Knight DA, Richards CD, Prêle CM, Lau HL, Jarnicki AG, Jones J, Bozinovski S, Vlahos R, Thiem S, et al: Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis. EMBO Mol Med. 4:939–951. 2012. View Article : Google Scholar : PubMed/NCBI
12	Yoshizaki A, Yanaba K, Ogawa A, Asano Y, Kadono T and Sato S: Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. Arthritis Rheum. 63:3575–3585. 2011. View Article : Google Scholar : PubMed/NCBI
13	Snedden WA and Fromm H: Characterization of the plant homologue of prohibitin, a gene associated with antiproliferative activity in mammalian cells. Plant Mol Biol. 33:753–756. 1997. View Article : Google Scholar : PubMed/NCBI
14	Merkwirth C and Langer T: Prohibitin function within mitochondria: Essential roles for cell proliferation and cristae morphogenesis. Biochim Biophys Acta. 1793:27–32. 2009. View Article : Google Scholar : PubMed/NCBI
15	Koushyar S, Jiang WG and Dart DA: Unveiling the potential of prohibitin in cancer. Cancer Lett. 369:316–322. 2015. View Article : Google Scholar : PubMed/NCBI
16	Peng YT, Chen P, Ouyang RY and Song L: Multifaceted role of prohibitin in cell survival and apoptosis. Apoptosis. 20:1135–1149. 2015. View Article : Google Scholar : PubMed/NCBI
17	Sharma A and Qadri A: Vi polysaccharide of Salmonella typhi targets the prohibitin family of molecules in intestinal epithelial cells and suppresses early inflammatory responses. Proc Natl Acad Sci USA. 101:17492–17497. 2004. View Article : Google Scholar : PubMed/NCBI
18	Theiss AL, Idell RD, Srinivasan S, Klapproth JM, Jones DP, Merlin D and Sitaraman SV: Prohibitin protects against oxidative stress in intestinal epithelial cells. FASEB J. 21:197–206. 2007. View Article : Google Scholar : PubMed/NCBI
19	Gamble SC, Chotai D, Odontiadis M, Dart DA, Brooke GN, Powell SM, Reebye V, Varela-Carver A, Kawano Y, Waxman J and Bevan CL: Prohibitin, a protein downregulated by androgens, represses androgen receptor activity. Oncogene. 26:1757–1768. 2007. View Article : Google Scholar : PubMed/NCBI
20	Theiss AL and Sitaraman SV: The role and therapeutic potential of prohibitin in disease. Biochim Biophys Acta. 1813:1137–1143. 2011. View Article : Google Scholar : PubMed/NCBI
21	Theiss AL, Vijay-Kumar M, Obertone TS, Jones DP, Hansen JM, Gewirtz AT, Merlin D and Sitaraman SV: Prohibitin is a novel regulator of antioxidant response that attenuates colonic inflammation in mice. Gastroenterology. 137(199–208): 208.e1–6. 2009.
22	Soulitzis N, Neofytou E, Psarrou M, Anagnostis A, Tavernarakis N, Siafakas N and Tzortzaki EG: Downregulation of lung mitochondrial prohibitin in COPD. Respir Med. 106:954–961. 2012. View Article : Google Scholar : PubMed/NCBI
23	Agrawal T, Gupta GK and Agrawal DK: Vitamin D deficiency decreases the expression of VDR and prohibitin in the lungs of mice with allergic airway inflammation. Exp Mol Pathol. 93:74–81. 2012. View Article : Google Scholar : PubMed/NCBI
24	Ko KS, Tomasi ML, Iglesias-Ara A, French BA, French SW, Ramani K, Lozano JJ, Oh P, He L, Stiles BL, et al: Liver-specific deletion of prohibitin 1 results in spontaneous liver injury, fibrosis and hepatocellular carcinoma in mice. Hepatology. 52:2096–2108. 2010. View Article : Google Scholar : PubMed/NCBI
25	Zhou TB, Qin YH, Lei FY, Huang WF and Drummen GP: Prohibitin attenuates oxidative stress and extracellular matrix accumulation in renal interstitial fibrosis disease. PLoS One. 8:e771872013. View Article : Google Scholar : PubMed/NCBI
26	Sanchez-Quiles V, Segura V, Bigaud E, He B, O'Malley BW, Santamaría E, Prieto J and Corrales FJ: Prohibitin-1 deficiency promotes inflammation and increases sensitivity to liver injury. J Proteomics. 75:5783–5792. 2012. View Article : Google Scholar : PubMed/NCBI
27	Hu X, Tian Y, Qu S, Cao Y, Li S, Zhang W, Zhang Z, Zhang N and Fu Y: Protective effect of TM6 on LPS-induced acute lung injury in mice. Sci Rep. 7:5722017. View Article : Google Scholar : PubMed/NCBI
28	Zhao J, He D, Su Y, Berdyshev E, Chun J, Natarajan V and Zhao Y: Lysophosphatidic acid receptor 1 modulates lipopolysaccharide-induced inflammation in alveolar epithelial cells and murine lungs. Am J Physiol Lung Cell Mol Physiol. 301:L547–L556. 2011. View Article : Google Scholar : PubMed/NCBI
29	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
30	Rocco PR, Dos SC and Pelosi P: Lung parenchyma remodeling in acute respiratory distress syndrome. Minerva Anestesiol. 75:730–740. 2009.PubMed/NCBI
31	Burnham EL, Janssen WJ, Riches DW, Moss M and Downey GP: The fibroproliferative response in acute respiratory distress syndrome: Mechanisms and clinical significance. Eur Respir J. 43:276–285. 2014. View Article : Google Scholar : PubMed/NCBI
32	Cottin V: Interstitial lung disease. Eur Respir Rev. 22:26–32. 2013. View Article : Google Scholar : PubMed/NCBI
33	Chapman HA: Epithelial-mesenchymal interactions in pulmonary fibrosis. Annu Rev Physiol. 73:413–435. 2011. View Article : Google Scholar : PubMed/NCBI
34	Dong WW, Zhang YQ, Zhu XY, Mao YF, Sun XJ, Liu YJ and Jiang L: Protective effects of hydrogen-rich saline against lipopolysaccharide-induced alveolar epithelial-to-mesenchymal transition and pulmonary fibrosis. Med Sci Monit. 23:2357–2364. 2017. View Article : Google Scholar : PubMed/NCBI
35	He D, Su Y, Usatyuk PV, Spannhake EW, Kogut P, Solway J, Natarajan V and Zhao Y: Lysophosphatidic acid enhances pulmonary epithelial barrier integrity and protects endotoxin-induced epithelial barrier disruption and lung injury. J Biol Chem. 284:24123–24132. 2009. View Article : Google Scholar : PubMed/NCBI
36	Zhao D, Ding R, Mao Y, Wang L, Zhang Z and Ma X: Heparin rescues sepsis-associated acute lung injury and lethality through the suppression of inflammatory responses. Inflammation. 35:1825–1832. 2012. View Article : Google Scholar : PubMed/NCBI
37	Zhu T, Wang DX, Zhang W, Liao XQ, Guan X, Bo H, Sun JY, Huang NW, He J, Zhang YK, et al: Andrographolide protects against LPS-induced acute lung injury by inactivation of NF-kappaB. PLoS One. 8:e564072013. View Article : Google Scholar : PubMed/NCBI
38	Zhou TB, Qin YH, Li ZY, Xu HL, Zhao YJ and Lei FY: All-trans retinoic acid treatment is associated with prohibitin expression in renal interstitial fibrosis rats. Int J Mol Sci. 13:2769–2782. 2012. View Article : Google Scholar : PubMed/NCBI
39	Theiss AL, Obertone TS, Merlin D and Sitaraman SV: Interleukin-6 transcriptionally regulates prohibitin expression in intestinal epithelial cells. J Biol Chem. 282:12804–12812. 2007. View Article : Google Scholar : PubMed/NCBI
40	Yuan C, Chen WX, Zhu JS, Chen NW, Lu YM, Ou YX and Chen HQ: IL-10 treatment is associated with prohibitin expression in the Crohn's disease intestinal fibrosis mouse model. Mediators Inflamm. 2013:6171452013. View Article : Google Scholar : PubMed/NCBI